Essential Pharma Acquires Renaissance Pharma Ltd

Lupin Healthcare Acquires Renascience Pharma Limited (UK)

April 2, 2025

Pharmaceuticals

Lupin Healthcare (UK) Limited, a wholly owned subsidiary of Lupin Limited, has acquired UK-based Renascience Pharma Limited, the sole supplier of four specialty branded products in the UK. The acquisition (reported at approximately £12.3 million) expands Lupin's branded specialty portfolio in the UK and strengthens its supply offerings to the NHS across infectious disease, ENT and cardiology/renal indications.

Essential Pharma Acquires Yorkdale Pharma from Rosemont; Sells Oral Liquid Portfolio to Rosemont and Buys Two Product Rights from Novartis

December 21, 2021

Pharmaceuticals

Gyrus Capital‑backed Essential Pharma completed a refinancing and executed a series of portfolio transactions in December 2021. Essential Pharma acquired Yorkdale Pharma Limited from Rosemont Pharmaceuticals, divested its 14‑product oral liquid portfolio (Essential Pharma Liquids Limited) to Rosemont, and also acquired worldwide (ex‑US, ex‑India) rights to two products from Novartis to expand its global specialty pharmaceutical portfolio.

Amgen Completes Acquisition of Horizon Therapeutics plc

October 6, 2023

Biotechnology

Amgen completed the acquisition of Horizon Therapeutics plc for $116.50 per share in cash, valuing the transaction at approximately $27.8 billion. The deal expands Amgen's inflammation and rare-disease portfolio by adding Horizon's medicines (including TEPEZZA, KRYSTEXXA and UPLIZNA) and strengthens Amgen's biologics R&D, manufacturing and global commercial capabilities.

NB Renaissance and Ardian to Acquire Majority Stake in Neopharmed Gentili

November 9, 2022

Pharmaceuticals

NB Renaissance won a beauty contest to partner with Ardian and acquire majority ownership of Italian pharmaceutical group Neopharmed Gentili via a 50/50 vehicle, valuing the company at about €1.4–1.5 billion. The Del Bono family (through Mediolanum Farmaceutici) will retain a minority stake while Ardian will sell its existing stake into the vehicle and reinvest alongside NB Renaissance to hold half of the vehicle.

ESTEVE Acquires HRA Pharma Rare Diseases from Perrigo

May 14, 2025

Pharmaceuticals

Barcelona-based ESTEVE completed the acquisition of HRA Pharma Rare Diseases (the rare-diseases business previously held by Perrigo) in July 2024, in a divestiture transaction announced by Perrigo for up to €275 million. The deal expands ESTEVE's rare-disease portfolio and strengthens its presence in Europe and the United States while supporting the company’s strategic focus on highly specialized therapies.

Pfizer Acquires Arena Pharmaceuticals

December 13, 2021

Pharmaceuticals

Pfizer Inc. agreed to acquire clinical-stage Arena Pharmaceuticals for $100 per share in an all-cash transaction valued at approximately $6.7 billion, creating a wholly owned subsidiary. The acquisition brings Arena's development-stage portfolio — including etrasimod and cardiovascular assets — into Pfizer's Inflammation & Immunology pipeline to accelerate clinical development and expand therapeutic capabilities.